Metabolic syndrome and the effect of testosterone treatment in young men with congenital hypogonadotropic hypogonadism

ObjectiveThe relationship between metabolic syndrome (MS) and hypogonadism has always been investigated in study groups confounded with aging, obesity or chronic metabolic disorders. So far, there has been no data about the presence of MS in young hypogonadal patients. Also, there is controversial d...

Full description

Saved in:
Bibliographic Details
Published in:European journal of endocrinology 2011-05, Vol.164 (5), p.759-764
Main Authors: Sonmez, A, Haymana, C, Bolu, E, Aydogdu, A, Tapan, S, Serdar, M, Altun, B, Barcin, C, Taslipinar, A, Meric, C, Uckaya, G, Kutlu, M
Format: Article
Language:English
Subjects:
Biological and medical sciences
Clinical Study
Endocrinopathies
Follow-Up Studies
Fundamental and applied biological sciences. Psychology
Hormone Replacement Therapy - adverse effects
Humans
Hypogonadism - blood
Hypogonadism - drug therapy
Hypothalamus. Hypophysis. Epiphysis (diseases)
Male
Medical sciences
Metabolic diseases
Metabolic Syndrome - blood
Metabolic Syndrome - chemically induced
Metabolic Syndrome - epidemiology
Miscellaneous
Non tumoral diseases. Target tissue resistance. Benign neoplasms
Other metabolic disorders
Retrospective Studies
Testosterone - adverse effects
Testosterone - therapeutic use
Vertebrates: endocrinology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ObjectiveThe relationship between metabolic syndrome (MS) and hypogonadism has always been investigated in study groups confounded with aging, obesity or chronic metabolic disorders. So far, there has been no data about the presence of MS in young hypogonadal patients. Also, there is controversial data about the metabolic effects of testosterone replacement therapy. We investigated the frequency of MS in treatment-naïve, young men with congenital hypogonadal hypogonadism (CHH). We also searched for the effect of testosterone replacement on the metabolic profiles of this specific patient group.DesignRetrospective analysis.MethodsA total of 332 patients (age 21.68±2.09 years) were enrolled. The control group included 395 age- and body mass index (BMI)-matched healthy young men (age 21.39±1.49 years). Standard regimen of testosterone esters (250 mg/3 weeks) was given to 208 patients.ResultsMS was more prevalent in CHH (P
ISSN:0804-4643
1479-683X
DOI:10.1530/EJE-10-0951